195 related articles for article (PubMed ID: 16450357)
1. Molecular cytogenetic characterization of doxorubicin-resistant neuroblastoma cell lines: evidence that acquired multidrug resistance results from a unique large amplification of the 7q21 region.
Flahaut M; Mühlethaler-Mottet A; Martinet D; Fattet S; Bourloud KB; Auderset K; Meier R; Schmutz NB; Delattre O; Joseph JM; Gross N
Genes Chromosomes Cancer; 2006 May; 45(5):495-508. PubMed ID: 16450357
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide.
Keshelava N; Davicioni E; Wan Z; Ji L; Sposto R; Triche TJ; Reynolds CP
J Natl Cancer Inst; 2007 Jul; 99(14):1107-19. PubMed ID: 17623797
[TBL] [Abstract][Full Text] [Related]
3. The Wnt receptor FZD1 mediates chemoresistance in neuroblastoma through activation of the Wnt/beta-catenin pathway.
Flahaut M; Meier R; Coulon A; Nardou KA; Niggli FK; Martinet D; Beckmann JS; Joseph JM; Mühlethaler-Mottet A; Gross N
Oncogene; 2009 Jun; 28(23):2245-56. PubMed ID: 19421142
[TBL] [Abstract][Full Text] [Related]
4. Establishment of cisplatin-resistant variants of human neuroblastoma cell lines, TGW and GOTO, and their drug cross-resistance profiles.
Iwasaki I; Sugiyama H; Kanazawa S; Hemmi H
Cancer Chemother Pharmacol; 2002 Jun; 49(6):438-44. PubMed ID: 12107547
[TBL] [Abstract][Full Text] [Related]
5. Increased malignant behavior in neuroblastoma cells with acquired multi-drug resistance does not depend on P-gp expression.
Kotchetkov R; Driever PH; Cinatl J; Michaelis M; Karaskova J; Blaheta R; Squire JA; Von Deimling A; Moog J; Cinatl J
Int J Oncol; 2005 Oct; 27(4):1029-37. PubMed ID: 16142320
[TBL] [Abstract][Full Text] [Related]
6. Cytogenetic alterations associated with P-glycoprotein- and non-P-glycoprotein-mediated multidrug resistance in SW-1573 human lung tumor cell lines.
Nieuwint AW; Baas F; Wiegant J; Joenje H
Cancer Res; 1992 Aug; 52(16):4361-71. PubMed ID: 1353703
[TBL] [Abstract][Full Text] [Related]
7. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC
Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145
[TBL] [Abstract][Full Text] [Related]
8. Evidence for cytoplasmic P-glycoprotein location associated with increased multidrug resistance and resistance to chemosensitizers.
Abbaszadegan MR; Cress AE; Futscher BW; Bellamy WT; Dalton WS
Cancer Res; 1996 Dec; 56(23):5435-42. PubMed ID: 8968098
[TBL] [Abstract][Full Text] [Related]
9. Molecular analysis of two human doxorubicin-resistant cell lines: evidence for differing multidrug resistance mechanisms.
Slovak ML; Coccia M; Meltzer PS; Trent JM
Anticancer Res; 1991; 11(1):423-8. PubMed ID: 1673331
[TBL] [Abstract][Full Text] [Related]
10. Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy.
Keshelava N; Seeger RC; Groshen S; Reynolds CP
Cancer Res; 1998 Dec; 58(23):5396-405. PubMed ID: 9850071
[TBL] [Abstract][Full Text] [Related]
11. Suppression of P-glycoprotein expression and multidrug resistance by DNA cross-linking agents.
Ihnat MA; Lariviere JP; Warren AJ; La Ronde N; Blaxall JR; Pierre KM; Turpie BW; Hamilton JW
Clin Cancer Res; 1997 Aug; 3(8):1339-46. PubMed ID: 9815817
[TBL] [Abstract][Full Text] [Related]
12. Amplification of 4q21-q22 and the MXR gene in independently derived mitoxantrone-resistant cell lines.
Knutsen T; Rao VK; Ried T; Mickley L; Schneider E; Miyake K; Ghadimi BM; Padilla-Nash H; Pack S; Greenberger L; Cowan K; Dean M; Fojo T; Bates S
Genes Chromosomes Cancer; 2000 Jan; 27(1):110-6. PubMed ID: 10564593
[TBL] [Abstract][Full Text] [Related]
13. Lentivirus-mediated RNA interference reversing the drug-resistance in MDR1 single-factor resistant cell line K562/MDR1.
Ye X; Liu T; Gong Y; Zheng B; Meng W; Leng Y
Leuk Res; 2009 Aug; 33(8):1114-9. PubMed ID: 19036441
[TBL] [Abstract][Full Text] [Related]
14. [Expression of the MDR1 gene in five human cell lines of medullary thyroid cancer and reversion of the resistance to doxorubicine by ciclosporin A and verapamil].
Massart C; Gibassier J; Lucas C; Pourquier P; Robert J
Bull Cancer; 1996 Jan; 83(1):39-45. PubMed ID: 8672855
[TBL] [Abstract][Full Text] [Related]
15. The MDR1/ABCB1 regional amplification in large inverted repeats with asymmetric sequences and microhomologies at the junction sites.
Kitada K; Yamasaki T
Cancer Genet Cytogenet; 2007 Oct; 178(2):120-7. PubMed ID: 17954267
[TBL] [Abstract][Full Text] [Related]
16. Altered expression of proliferation-inducing and proliferation-inhibiting genes might contribute to acquired doxorubicin resistance in breast cancer cells.
Saleh EM; El-Awady RA; Abdel Alim MA; Abdel Wahab AH
Cell Biochem Biophys; 2009; 55(2):95-105. PubMed ID: 19593673
[TBL] [Abstract][Full Text] [Related]
17. The LRP gene encoding a major vault protein associated with drug resistance maps proximal to MRP on chromosome 16: evidence that chromosome breakage plays a key role in MRP or LRP gene amplification.
Slovak ML; Ho JP; Cole SP; Deeley RG; Greenberger L; de Vries EG; Broxterman HJ; Scheffer GL; Scheper RJ
Cancer Res; 1995 Oct; 55(19):4214-9. PubMed ID: 7671223
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of anticancer effects of newly synthesized dihydropyridine derivatives in comparison to verapamil and doxorubicin on T47D parental and resistant cell lines in vitro.
Bazargan L; Fouladdel S; Shafiee A; Amini M; Ghaffari SM; Azizi E
Cell Biol Toxicol; 2008 Apr; 24(2):165-74. PubMed ID: 17805981
[TBL] [Abstract][Full Text] [Related]
19. P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5.
Park SJ; Wu CH; Choi MR; Najafi F; Emami A; Safa AR
Biochem Pharmacol; 2006 Jul; 72(3):293-307. PubMed ID: 16753135
[TBL] [Abstract][Full Text] [Related]
20. Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival.
Györffy B; Serra V; Jürchott K; Abdul-Ghani R; Garber M; Stein U; Petersen I; Lage H; Dietel M; Schäfer R
Oncogene; 2005 Nov; 24(51):7542-51. PubMed ID: 16044152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
